comparemela.com

Latest Breaking News On - Debbie etchison - Page 1 : comparemela.com

Scynexis: SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment

David anguloDebbie etchisonIrina kofflerTriterpenoid antifungalsExchange commissionScynexis incEuropean congressDrug administrationChief executive officerLicense agreementScientific presentationsAnnual european congressClinical microbiologyInfectious diseasesMedical affairsPrivate securities litigation reform act

GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with. | March 30, 2023

United statesUnited kingdom generalUnited kingdomNew yorkCity ofJeff mclaughlinLuke mielsJames dodwellDavid anguloDan smithTim foleyCamilla campbellLyndsay meyerIrina kofflerNick stoneJosh williams

SCYNEXIS, Inc (SCYX) Q3 2022 Earnings Call Transcript

SCYNEXIS, Inc. (NASDAQ:NASDAQ:SCYX) Q3 2022 Results Conference Call November 9, 2022 08:30 AM ET Company Participants Debbie Etchison - Communications & IR Dr.

United statesLouise chenDebbie etchisonMarco tagliettiShubhendu sen royMichael higginsDavid anguloIvor macleodExchange commissionCompany participantsLadenburg thalmannWorld health organizationScynexis incConference call novemberSen royExecutive director

SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting

Approximately 83% of FURI patients with refractory Candida infections had positive clinical outcomes, defined as complete/partial response or no disease progression . Data from the ongoing Phase. | September 8, 2022

Irina kofflerDebbie etchisonNkechi azieResearch consortiumDrug administrationScynexis incMycoses study group educationEuropean medicines agencyGlobenewswire incClinical developmentStudy group educationBiennial meetingVice presidentMedical affairsQualified infectious disease productFast track

SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update

15.08.2022 - BREXAFEMME (ibrexafungerp tablets) prescriptions in Q2 2022 increased 29 percent over Q1 2022, generating net revenues of $1.3 million in Q2 2022, compared to $0.7 million in Q1. SCYNEXIS filed a supplemental New Drug Application (sNDA) to expand .

San diegoUnited statesIrina kofflerDebbie etchisonEuropean congressInfectious diseases society for obstetricsDrug administrationScynexis incExchange commissionData review committeeAmerican college of obstetriciansWorld congressInternational vulvovaginal diseasePriority reviewPrescription drug user fee actScientific presentations

vimarsana © 2020. All Rights Reserved.